



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Date: 19.06.2026

To,
Department of Corporate Services,
BSE Limited.
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001

Scrip Code: 524400

Dear Sir/Madam,

Sub: Disclosure under regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

With Reference to the captioned subject, please find enclosed the disclosure under regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011:

- a) Acquisition of 55 shares of Rs. 10/- each by Ishita Pharmaceuticals, related party of Ishita Drugs and Industries Ltd.

Please take the above disclosure on record.

Thanking You,

For, Ishita Drugs and Industries Limited

Abha Agrawal
Director
DIN: 01589479

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359

ISHITA PHARMACEUTICALS

Phone: 91 -79 -26468353/7886, Email: ishitapharma1980@gmail.com
Factory: 65/1, GIDC Industrial Estate, Wadhawan - 363035, Surendranagar, India.

Date: 19.06.2026

To,
Department of Corporate Services,
BSE Limited.
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001

Ishita Drugs & Industries Ltd.
Office No: 401, 3rd Eye II,
Opp. Parimal Garden, C.G. Road,
Ahmedabad - 380 006

Scrip Code: 524400

Dear Sir/Madam,

Sub: Disclosure under regulation 29(2) of SEBI (Substantial Acquisition of Shares & takeovers) Regulations, 2011

With Reference to the captioned subject, Ishita Pharmaceuticals, related party of Ishita Drugs and Industries Limited, do hereby inform you that we have acquired 55 shares of Rs. 10/- each of Ishita Drugs & Industries Ltd.

Please find enclosed the necessary disclosure as required under regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Kindly, take the above information on your record.

Thanking you,

Yours Faithfully,

For Ishita Pharmaceuticals

For, ISHITA PHARMACEUTICALS

Partner

Partner/Constituted Attorney

ISHITA PHARMACEUTICALS

Phone: 91 -79 -26468353/7886, Email: ishitapharma1980@gmail.com
 Factory: 65/1, GIDC Industrial Estate, Wadhawan – 363035, Surendranagar, India.

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Ishita Drugs and Industries Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Ishita Pharmaceuticals		
Whether the acquirer belongs to Promoter/Promoter group	Related Party of the Target Company		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a) Shares carrying voting rights	32642	1.09	1.09
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	Nil	Nil
c) Voting rights (VR) otherwise than by shares	Nil	Nil	Nil
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	Nil	Nil	Nil
e) Total (a+b+c+d)	32642	1.09	1.09

ISHITA PHARMACEUTICALS

Phone: 91 -79 -26468353/7886, Email: ishitapharma1980@gmail.com
 Factory: 65/1, GIDC Industrial Estate, Wadhawan – 363035, Surendranagar, India.

Details of acquisition			
a) Shares carrying voting rights acquired/sold	55	0.00	0.00
b) VRs acquired /sold otherwise than by shares	Nil	Nil	Nil
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	Nil	Nil	Nil
d) Shares encumbered / invoked/released by the acquirer	Nil	Nil	Nil
e) Total (a+b+c+d)	55	0.00	0.00
After the acquisition, holding of:			
a) Shares carrying voting rights	32697	1.09	1.09
b) Shares encumbered with the acquirer	NIL	NIL	NIL
c) VRs otherwise than by shares	NIL	NIL	NIL
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	NIL	NIL	NIL
e) Total (a+b+c+d)	32697	1.09	1.09
Mode of acquisition	Open Market		
Date of acquisition	June 19, 2026		
Equity share capital of the Target Company before the said acquisition	Rs. 29903000/- (2990300 shares of Rs.10 each)		
Equity share capital of the Target Company after the said acquisition	Rs. 29903000/- (2990300 shares of Rs.10 each)		
Total diluted share/voting capital of the Target Company after the said acquisition	Rs. 29903000/- (2990300 shares of Rs.10 each)		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For Ishita Pharmaceuticals

For, **ISHITA PHARMACEUTICALS**

Partner

Partner/Constituted Attorney